GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » IRIDEX Corp (NAS:IRIX) » Definitions » PE Ratio

IRIDEX (IRIDEX) PE Ratio

: At Loss (As of Today)
View and export this data going back to 1996. Start your Free Trial

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-04-16), IRIDEX's share price is $3.17. IRIDEX's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.59. Therefore, IRIDEX's PE Ratio for today is At Loss.


The historical rank and industry rank for IRIDEX's PE Ratio or its related term are showing as below:

IRIX' s PE Ratio Range Over the Past 10 Years
Min: At Loss   Med: 46.77   Max: 725
Current: At Loss


During the past 13 years, the highest PE Ratio of IRIDEX was 725.00. The lowest was 0.00. And the median was 46.77.


IRIX's PE Ratio is ranked worse than
100% of 408 companies
in the Medical Devices & Instruments industry
Industry Median: 26.945 vs IRIX: At Loss

IRIDEX's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.18. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.59.

As of today (2024-04-16), IRIDEX's share price is $3.17. IRIDEX's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.59. Therefore, IRIDEX's PE Ratio without NRI for today is At Loss.

During the past 13 years, IRIDEX's highest PE Ratio without NRI was 725.00. The lowest was 0.00. And the median was 47.04.

IRIDEX's EPS without NRI for the three months ended in Dec. 2023 was $-0.18. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.59.

During the past 3 years, the average EPS without NRI Growth Rate was -8.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was 11.10% per year.

During the past 13 years, IRIDEX's highest 3-Year average EPS without NRI Growth Rate was 211.80% per year. The lowest was -197.30% per year. And the median was 11.10% per year.

IRIDEX's EPS (Basic) for the three months ended in Dec. 2023 was $-0.18. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.59.


IRIDEX PE Ratio Historical Data

The historical data trend for IRIDEX's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IRIDEX Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PE Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

IRIDEX Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PE Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Competitive Comparison

For the Medical Devices subindustry, IRIDEX's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IRIDEX PE Ratio Distribution

For the Medical Devices & Instruments industry and Healthcare sector, IRIDEX's PE Ratio distribution charts can be found below:

* The bar in red indicates where IRIDEX's PE Ratio falls into.



IRIDEX PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

IRIDEX's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=3.17/-0.590
=At Loss

IRIDEX's Share Price of today is $3.17.
IRIDEX's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.59.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio or PE Ratio (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


IRIDEX  (NAS:IRIX) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


IRIDEX PE Ratio Related Terms

Thank you for viewing the detailed overview of IRIDEX's PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


IRIDEX (IRIDEX) Business Description

Traded in Other Exchanges
N/A
Address
1212 Terra Bella Avenue, Mountain View, CA, USA, 94043
IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
Executives
Nandini Devi director 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Beverly A Huss director C/O ACCURAY INCORPORATED, 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Robert Earle Grove director 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Topcon Corp 10 percent owner 75-1, HASUNUMA-CHO, ITABASHI-KU, TOKYO M0 174-8580
Topcon America Corp 10 percent owner 111 BAUER DRIVE, OAKLAND NJ 07426
Fuad Ahmad officer: Interim CFO 461 SOUTH MILPITAS BLVD., MILPITAS CA 95035
Doris Engibous director C/O NATUS MEDICAL INCORPORATED, 1501 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Scott Shuda director 402 RAILROAD AVENUE, SUITE 201, DANVILLE CA 94526
Patrick Mercer officer: COO 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Maria Sainz director C/O ORTHOFIX INTERNATIONAL N. V., 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Ruediger Naumann-etienne director
Robert A Gunst director
David Bruce director, officer: President and CEO 1178 GLEN ROAD, LAFAYETTE CA 94549
Ken Ludlum director
Romeo R Dizon other: Vice President and Controller 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043

IRIDEX (IRIDEX) Headlines

From GuruFocus

Iridex Announces First Quarter 2022 Financial Results

By GuruFocusNews GuruFocusNews 05-12-2022

Iridex Announces First Quarter 2022 Financial Results

By PurpleRose PurpleRose 07-11-2022

Iridex to Report First Quarter Financial Results on May 11, 2023

By sperokesalga sperokesalga 04-27-2023

Iridex to Present at the 34th Annual Roth Conference

By GuruFocusNews GuruFocusNews 03-08-2022

Iridex to Participate in Fireside Chat with Stifel Equity Research

By Value_Insider Value_Insider 12-06-2022

Iridex to Participate in Fireside Chat with Stifel Equity Research

By GlobeNewswire GlobeNewswire 12-06-2022